The effect of CD56 positive on prognosis of patients with acute promyelocytic leukemia
CHEN Yuemiao1, YU Kang2, ZHENG Cuiping1, ZHOU Wenjin1, LIU Zhen1
1.Department of Hematology, the Dingli Clinical Institute Affiliated to Wenzhou Medical University, Wenzhou Central Hospital, Wenzhou 325000, China; 2.Department of Hematology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325015, China
CHEN Yuemiao,YU Kang,ZHENG Cuiping, et al. The effect of CD56 positive on prognosis of patients with acute promyelocytic leukemia[J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2019, 49(2): 96-99.
目的：观察CD56抗原在新发成人急性早幼粒细胞白血病（APL）患者中的表达情况，分析其免疫特点及对预后的影响。方法：分析2007年5月至2012年10月在温州市中心医院就诊的新发成人APL病例的临床资料并进行随访，根据流式细胞术测定的患者骨髓CD56抗原的表达情况，将患者分成CD56阳性组与CD56阴性组，比较2组患者的免疫特点及预后差别。结果：64例患者中CD56阳性者12例，阴性者52例，阳性率为18.75%。2组患者的CD9、CD11b、CD15、CD19、CD117、HLA-DR抗原表达差异均无统计学意义（P＞0.05）；CD56阳性组CD2及CD34表达率较阴性组高（分别25.00% vs. 3.85%，P=0.042；41.67% vs. 3.85%，P=0.001）。预后方面，2组患者的完全缓解率、复发率、中位总生存期及3年总生存率的差异无统计学意义（P＞0.05），但CD56阳性组髓外复发率较阴性组高（27.27% vs. 4.55%， P＜0.05），3年无病生存率也低于阴性组（54.55% vs. 86.36％，P＜0.05）。结论：CD56抗原阳性是新发成人APL患者预后不良的影响因素之一。
Abstract：Objective: To investigate the expression of CD56 antigen in de-novo acute promyelocytic leukemia (APL) and to analyze the immuno-features and surviva1 of patients with positive CD56 expression.Methods: The expression of CD56 in bone marrow was detected by flow cytometry. Patients of de-novo acute promyelocytic leukemia who visited Wenzhou Central Hospital from May 2007 to October 2012 were followed up and their clinical data were analyzed. Immuno-features and prognosis were compared between patients expressing and nonexpressing CD56. Results: Of 64 patients, 12 (18.75%) were positive for CD56. There were no statistical differences in terms of CD9, CD11b, CD15, CD19, CD117, HLA-DR surface antigen markers between CD56+ and CD56- groups (P>0.05). Expressions of CD56 were significantly associated with coexpression of CD2 and CD34 (25.00% vs. 3.85%, P=0.042; 41.67% vs. 3.85%, P=0.001). The complete remission, relapse rate, 3-year median overall survival (OS) period and 3-year overall survival rate showed no significant differences between CD56+ and CD56- groups (P>0.05), while extramedullary relapse rate (27.27% vs. 4.55%, P<0.05), 3-year disease free-survival (DFS) rate (54.55% vs. 86.36%, P<0.05) indicated significant differences. Conclusion: The expression of CD56 appeared to be one of adverse prognostic factors in de-novo APL.
[1] SUZUKI R, OHTAKE S, TAKEUCHI J, et a1. The clinical characteristics of CD7+ CD56+ acute myeloid leukemias other than M0[J]. Int J Hematol, 2010, 91(2): 303-309.
[2] 马荣军, 朱尊民, 袁晓莉, 等. 成人急性早幼粒细胞白血病预后相关因素分析[J]. 中华血液学杂志, 2017, 38(7): 592-596.
[3] 宋斌, 陈雁, 吴修伟, 等. 176例成人急性髓细胞白血病免疫表型分析及其与疗效、复发关系的研究[J]. 标记免疫分析与临床, 2016, 23(11): 1337-1340.
[4] 张之南, 沈悌. 血液病诊断及疗效标准[M]. 北京: 科学出版社, 2007.
[5] 陈芳, 胡延平, 王孝会, 等. 急性早幼粒细胞白血病免疫表型特点[J]. 中国实验血液学杂志, 2016, 24(2): 321-325.
[6] 宫丹, 李薇, 胡亮钉, 等. 中国t(8;21)AML患者临床特征及预后分析: 一项多中心回顾性研究[J]. 中国实验血液学杂志, 2017, 25(4): 980-986.
[7] 赵慧慧, 黄佳瑜, 朱雨, 等. CD56阳性老年急性髓系白血病患者的临床特征及预后分析[J]. 老年医学与保健, 2017, 16(21): 2125-2128.
[8] ITO S, ISHIDA Y, OYAKE T, et al. Clinical and biological significance of CD56 antigen expression in acute promyelocytic leukemia[J]. Leuk Lymphoma, 2004, 45(9): 1783-1789.
[9] MONTESINOS P, RAYON C, VELLENGA E, et al. Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-transretinoic acid and anthracycline-based regimens[J]. Blood, 2011, 117(6): 1799-1805.
[10] ONO T, TAKESHITA A, Kishimoto Y, et al. Expression of CD56 is an unfavorable prognosticfactor for acute promyelocytic leukemia with higherinitial white blood cell counts [J]. Cancer Sci, 2014, 105(1): 97-104.
[11] LAUNDER T M, BRAY R A, STEMPORA L, et al. Lymphoid-associated antigen expression by acute myeloid leuke-mia[J]. Am J Clin Pathol, 1996, 106(2): 185-191.
[12] CHAPIRO E, DELABESSE E, ASNAFI V, et al. Expression of T-lineage-affiliated transcripts and TCR rearrangements in acute promyelocytic leukemia: implications for the cellular target of t (15;17)[J]. Blood, 2006, 108(10): 3484-3493.
[13] XU F, YIN C X, WANG C L, et al. Immunophenotypes and immune markers associated with acute promyelocytic leukemia prognosis[J]. Dis Markers, 2014, 2014: 421906.
[14] KAITO K, KATAYAMA T, MASUOKA H, et al. CD2+ acute promyelocytic leukemia is associated with leukocytosis, variant morphology and poorer prognosis[J]. Clin Lab Haematol, 2005, 27(5): 307-311.
[15] 董婷, 蒋雅先, 李正发, 等. 急性早幼粒细胞白血病的细胞表面免疫分子的检测和分析[J]. 细胞与分子免疫学杂志, 2017, 33(5): 664-667, 676.
[16] 刘玉玉, 焦玉燕, 李斑斑, 等. 急性早幼粒细胞白血病早期死亡危险因素分析[J]. 中国现代医生, 2015, 53(16): 15-17.
[17] FERRARA F, MORABITO F, MARTINO B, et al. CD56 expression is an indicator ofpoor clinical outcome in patients with acute promyelocytic leukemia treatedwith simultaneous all-trans-retinoic acid and chemotherapy[J]. J Clin Oncol, 2000, 18(6): 1295-1300.
[18] DE LA SERNA J, MONTESINOS P, VELLENGA E, et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin[J]. Blood, 2008, 111(7): 3395-3402.
[19] ILAND H J, BRADSTOCK K, SUPPLE S G, et al. All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)[J]. Blood, 2012, 120: 1570-1580.
[20] TIWARI D, BOSE P D, SULTANA R, et al. Preterm delivery and associated negative pregnancy outcome-A tale of faulty progesterone receptor signalling pathway and linked derailed immunomodulation: A study from Northeast India [J]. J Reprod Immunol, 2016, 118: 76-84.
